ArticleJournal of thoracic disease2025
Predictive and prognostic value of genetic aberrations of EGFR-TKI treatment: a real-world analysis of
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard first-line therapy for patients with Methods: Overall, 102 patients were enrolled. The clinical data of 77 patients with Results: In the discovery cohort, the median progression-free survival (PFS) was 17.20 months and the median overall survival (OS) was 37.47 months. A history of smoking [hazard ratio (HR) 2.25, 95% confidence interval (CI): 0.99-5.12, P=0.046] and male sex (HR 2.18, 95% CI: 1.03-4.60, P=0.04) were significantly associated with poor outcomes. Treatment with third-generation EGFR-TKIs significantly prolonged PFS compared with first- and second-generation TKIs (HR 3.01, 95% CI: 1.17-7.73, P=0.02). Conclusions: This study identified key biomarkers associated with the efficacy of EGFR-TKIs and survival in patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.